Pharma
Galvus Met (Vildagliptin/Metformin HCl 50 mg/850 mg)
Combination DPP-4 inhibitor and Biguanide; 50mg/850mg Vildagliptin/Metformin tablets for Type 2 Diabetes management.
Galvus Met (Vildagliptin/Metformin HCl 50 mg/850 mg)
Galvus Met is a combination oral antidiabetic medication containing Vildagliptin and Metformin Hydrochloride. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances pancreatic insulin secretion, while Metformin reduces glucose production in the liver and improves insulin sensitivity. Together, they are used to improve glycemic control in adults with type 2 diabetes mellitus when diet, exercise, and monotherapy do not provide adequate control. This medication is not for type 1 diabetes or diabetic ketoacidosis. Common side effects include nausea, headache, dizziness, and gastrointestinal upset.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.